Fernando Barroso Duarte, MD, Federal University of Ceara, Fortaleza, Brazil, discusses the relevance of the Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndromes (MDS) during stem cell transplantation (SCT) in the molecular classification era. Prof. Barroso Duarte outlines the results of a study showing that in countries where access to molecular data is limited, the IPSS-R can still be used to risk stratify patients. Prof. Barroso Duarte also highlights the importance of risk stratifying patients prior to SCT, and of better defining how the molecular-IPSS (IPSS-M) can be used in clinical practice. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.